Assessing the magnitude of the protective effect of SGLT-2 inhibitors on these outcomes based on the presence or absence of chronic kidney disease (CKD) at baseline remains an important question in order to confirm whether their therapeutic effect is independent of kidney function4. The gene discussed is SLC5A2; the disease is chronic kidney disease.